# Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

> **NCT00003514** · PHASE2 · WITHDRAWN · sponsor: **Burzynski Research Institute**

## Conditions studied

- Merkel Cell Carcinoma
- Islet Cell Carcinoma
- Neuroendocrine Carcinoma
- Pituitary Tumor

## Interventions

- **DRUG:** antineoplaston A10
- **DRUG:** antineoplaston AS2-1
- **PROCEDURE:** alternative product therapy
- **PROCEDURE:** biological therapy
- **PROCEDURE:** biologically based therapies
- **PROCEDURE:** cancer prevention intervention
- **PROCEDURE:** complementary and alternative therapy
- **PROCEDURE:** differentiation therapy

## Key facts

- **NCT ID:** NCT00003514
- **Lead sponsor:** Burzynski Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003514, "Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*